The Institute of Cancer Research joins the Elekta and Philips research consortium to develop MRI-guided therapy system for cancer treatment

LONDON, June 5, 2014 – Elekta (NSE:EKTAb) and Royal Philips (NYSE:PHG, AEX:PHIA)
announced today that The Institute of Cancer Research, London, a world-leading
cancer research institution, working with its clinical partner The Royal Marsden
NHS Foundation Trust, will join the Elekta MR Linac Research Consortium, a group
with a mission to develop an integrated magnetic resonance imaging (MRI) guided
radiation therapy system. Uniting an advanced digital linac with an MRI system
would greatly enhance real-time visualization of cancer targets during the
delivery of therapeutic radiation.
“The addition of The Institute of Cancer Research (ICR) to the consortium
further strengthens this growing partnership of clinical centers,” says Niklas
Savander, Elekta President and CEO. “The ICR is a prominent cancer research
institute and has contributed significantly in this arena for over a century.
Its unique partnership with The Royal Marsden and ‘bench-to-bedside’ approach
allows the ICR to deliver exceptional results. All of these factors make the ICR
and The Royal Marsden a perfect fit as we advance MRI-guided radiotherapy.”

“The development of MRI-guided radiation therapy establishes a new vision for
clinical radiation oncology for the treatment of cancer,” says Prof. Uwe Oelfke,
MCCPM, FInstP, and Head of the Joint Department of Physics at The Institute of
Cancer Research, London and The Royal Marsden NHS Foundation Trust. “The
translation of this novel technical approach into clinical practice faces a
number of challenges ideally addressed by a group of world leading radiotherapy
centers, each contributing with its specific expertise. Being a member of the
consortium is a prerequisite to shape this exciting future of radiation therapy.

“Our current Cancer Research UK-funded research program on adaptive and image
guided therapy,” he continues, “together with the activities on MRI within our
Cancer Research UK imaging center, are an excellent research environment to make
leading contributions to the joint efforts of the consortium.”

The ICR’s initial research focus for MRI-guided radiation therapy will be on
pelvic malignancies, where the excellent soft tissue contrast of MR images
directly before or during treatment will substantially enhance treatment options
and quality, he adds.

The ICR is the sixth member to join the research consortium that assesses the
novel technology, which brings together state-of-the-art radiation therapy and
MRI in a single system. The consortium also includes the University Medical
Center Utrecht (Utrecht, the Netherlands), The University of Texas MD Anderson
Cancer Center (Houston, Texas), The Netherlands Cancer Institute-Antoni van
Leeuwenhoek Hospital (Amsterdam, the Netherlands), Sunnybrook Health Sciences
Centre (Toronto, Ontario) and The Froedtert & Medical College of Wisconsin
Cancer Center (Milwaukee, Wisconsin).

“MRI-guided radiation therapy has the promise to become a highly targeted
treatment for cancer,” said Gene Saragnese, CEO Imaging Systems at Philips
Healthcare. “The realization of this promise requires the collaboration between
leaders in interventional imaging and radiation therapy delivery, as well as
clinical innovators in oncology. We are convinced that the deep clinical
knowledge and expertise of the Institute of Cancer Research will be a strong
asset to the growing research consortium.”

Major progress
Since its launch in 2012, the research consortium has taken several steps toward
its goal.

On April 5, the University Medical Center Utrecht began installing the first
generation MRI-guided radiation therapy system for non-clinical testing, which
includes the performance evaluation of MRI pulse sequences, testing of different
adaptive delivery methods, establishing quality assurance techniques and
defining workflow. Several of the sites are now undertaking treatment planning
evaluation using the Monte Carlo based MRI-corrected algorithms in a research
version of Elekta’s Monaco® treatment planning system. In addition, A number of
the consortium centers have active research programs linked to the MRI-guided
radiation therapy system and have submitted abstracts to the American
Association of Physicists in Medicine [AAPM] Annual Meeting (July 20-24, Austin,
Texas) where some specific sessions will be covering the latest advances in MRI
-guided radiotherapy.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time

Steve Klink, Philips Group Communications
Tel: +31 6 10888824, e-mail: steve.klink@philips.com
Time zone: CET: Central European Time

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on June 5, 2014.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,500 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker STO:EKTAB. Website:
www.elekta.com.

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being
company, focused on improving people’s lives through meaningful innovation in
the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the
Netherlands, Philips posted 2013 sales of EUR 23.3 billion and employs
approximately 112,000 employees with sales and services in more than 100
countries. The company is a leader in cardiac care, acute care and home
healthcare, energy efficient lighting solutions and new lighting applications,
as well as male shaving and grooming and oral healthcare. News from Philips is
located at www.philips.com/newscenter.